Nevada 2025 Regular Session

Nevada Assembly Bill AB304

Introduced
2/27/25  
Refer
2/27/25  
Report Pass
4/16/25  
Refer
4/17/25  
Report Pass
5/28/25  
Engrossed
5/31/25  
Refer
5/31/25  
Report Pass
6/1/25  
Failed
6/3/25  
Enrolled
6/6/25  
Chaptered
6/11/25  

Caption

Establishing certain notification and reporting requirements concerning pilot programs that research transcranial magnetic stimulation or electromagnetic brain pulse treatment. (BDR S-865)

Impact

The implications of AB304 on state laws include the establishment of clear guidelines for the conduct of research related to TMS and electromagnetic brain pulse treatment. By mandating pre-implementation notifications and quarterly reports, the bill seeks to ensure that research activities adhere to ethical standards and are properly monitored. The requirement for final reports upon completion of the pilot programs will contribute to a repository of knowledge regarding these advanced treatment methodologies, potentially influencing future healthcare practices and policies.

Summary

Assembly Bill 304 (AB304) establishes notification and reporting requirements for practitioners or entities conducting pilot programs that research transcranial magnetic stimulation (TMS) or electromagnetic brain pulse treatment. The bill aims to create a framework for oversight by requiring these practitioners to notify the Director of the Legislative Counsel Bureau before starting any research and to provide ongoing reports throughout the duration of the pilot program. This structured approach is intended to enhance transparency and accountability in healthcare research within the state.

Sentiment

The sentiment surrounding AB304 appears generally positive, with support from lawmakers and professionals who see the need for regulated research practices in the emerging field of mental health treatments. Proponents argue that the bill will help safeguard the interests of participants in clinical studies while promoting innovative therapies. However, there may be some concern regarding the bureaucratic process that such requirements could impose on researchers, possibly affecting the pace of advancements in mental health treatment.

Contention

Notable points of contention regarding AB304 may include discussions about the balance between regulation and innovation. While proponents advocate for oversight to protect research subjects and ensure ethical standards, critics may argue that excessive regulatory requirements could deter practitioners from exploring new treatment options. Furthermore, clarity regarding the collaborative efforts with institutions of higher learning and the implications of funding sources, such as grants, could form additional areas of debate as the bill is considered.

Companion Bills

No companion bills found.

Previously Filed As

NV AB188

Revises provisions governing investigational treatments. (BDR 40-567)

NV SB402

Creates the Cannabis Mentorship Pilot Program. (BDR 56-1064)

NV SB177

Imposes requirements governing Medicaid coverage of certain antipsychotic or anticonvulsant drugs. (BDR 38-82)

NV SB283

Revises certain provisions relating to health care . (BDR 54-555)

NV AB348

Creates the Virtual Early Childhood Family Engagement Pilot Program in the Department of Health and Human Services. (BDR S-988)

NV SB329

Requires appointment of a committee to study provisions relating to budgetary and reporting requirements for school districts. (BDR S-443)

NV AB517

Revises provisions governing the Legislative Counsel Bureau. (BDR 17-447)

NV SB144

Establishes a credit against certain taxes for a taxpayer who donates money to a career and technical program tax credit organization that makes grants to programs of career and technical education. (BDR 34-866)

NV SB80

Revises provisions relating to the prevention and treatment of injuries to the head. (BDR 34-549)

NV AB463

Revises provisions governing child care facilities and certain child care programs. (BDR 38-1083)

Similar Bills

CA AB3095

Health care practitioners: stem cell therapy.

US SB331

HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

CA AB1751

Controlled substances: CURES database.

US HB467

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

US HB27

HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

US HB171

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

US SB1141

HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

PA SB835

In preliminary provisions, further providing for definitions; in program, further providing for program established, for confidentiality and public disclosure, for lawful use of medical marijuana and for unlawful use of medical marijuana; in practitioners, further providing for practitioner registration, for practitioner restrictions, for issuance of certification and for duration; in patients, further providing for identification cards, for verification and for contents of identification card; in medical marijuana organizations, further providing for granting of permit, for relocation and for limitations on permits; in medical marijuana controls, further providing for electronic tracking, for grower/processors, for storage and transportation, for laboratory and for prices and providing for recalls; in dispensaries, further providing for dispensing to patients and caregivers and for facility requirements; in tax on medical marijuana, further providing for Medical Marijuana Program Fund; in Medical Marijuana Advisory Board, further providing for advisory board; in research program, further providing for establishment of medical marijuana research program, for medical marijuana research program administration and for approval; in academic clinical research centers and clinical registrants, further providing for legislative findings and declaration of policy, for definitions and for clinical registrants and providing for termination of contract; and, in miscellaneous provisions, further providing for applicability.